<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444819</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EMSI-201</org_study_id>
    <nct_id>NCT02444819</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy</brief_title>
  <official_title>A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, single-arm. Phase 2 exploratory trial to evaluate the efficacy and safety of
      HM61713 as the 1st-line anticancer agent in none-small cell lung cancer patients with EGFR
      mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HM-EMSI-201 study targets NSCLC patients with EGFR mutations by HM61713 anticancer drug as
      the first-line therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year</time_frame>
    <description>To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year</time_frame>
    <description>To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year</time_frame>
    <description>To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year</time_frame>
    <description>To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year</time_frame>
    <description>To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease in tumor size</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year</time_frame>
    <description>To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>At baseline and every visit, expected average 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>HM61713</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who entered the study will be administered HM61713 800 mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM61713</intervention_name>
    <description>HM61713 will be administered to evaluate efficacy and safety of subjects.</description>
    <arm_group_label>HM61713</arm_group_label>
    <other_name>Olmutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 19 years at the time of signing informed consent

          -  Cytologically or histologically confirmed, advanced or metastatic NSCLC which is not
             amenable to curative surgery (Stage IIIb or IV)

          -  Documented EGFR mutations (excluding exon 20 insertion)

          -  At least one lesion that can be used as a measurable lesion per RECIST version 1.1

          -  Performance status under 1 per ECOG score

          -  Life expectancy of at least 12 weeks

          -  Adequate hematological and biological functions

          -  Provide voluntary consent to participate the study and sign the written consent form

        Exclusion Criteria:

          -  Treatment of chemotherapy, biological therapy or immunotherapy for anticancer
             therapies of stage IIIb or IV NSCLC (excluding adjuvant/neoadjuvant chemotherapy,
             radiotherapy or radiochemotherapy prior to more than 6 months from the first dose of
             study treatment

          -  History of treatment with an EGFR targeting small molecule or antibodies

          -  Any non-study related significant surgical procedures requires general anesthesia or
             breathing apparatus within the past 4 weeks of the first dose of study treatment
             (excluding video-assisted thoracoscopic surgery or open-and-closed surgery prior to
             the past 2 weeks of the first dose of study treatment)

          -  History of any other malignancy within 5 years of study participation (other than
             curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial
             bladder tumors unless it has been definitively treated with no evidence of relapse or
             recurrence within the past 3 years)

          -  Clinically significant uncontrolled conditions of infectious disease including active
             infection that requires parenteral antibiotics (except when conditions are
             definitively treated or controlled)

          -  Spinal cord compression, leptomeningeal carcinomatosis, symptomatic or uncontrolled
             brain metastasis

          -  Presence or history of ILD or pulmonary fibrosis

          -  NYHA class III or IV cardiac insufficiency, uncontrolled hypertension, experienced
             unstable angina pectoris or cardiac infarction within 6 months, uncontrolled cardiac
             arrhythmia or clinically significant abnormal cardiovascular activities

          -  LVEF &lt; 40%

          -  Presence or history of pancreatitis or serum amylase &gt; 1.5xULN

          -  Inability to swallow the formulated product or gastrointestinal tract abnormalities
             which would preclude administration or absorption of study medication

          -  Mental or congenital disabilities (e.g. dementia or epilepsy) which would preclude
             understanding of informed consent or following the study protocol

          -  History of hypersensitivities to investigational drug or related similar class drugs

          -  Pregnant or breast feeding

          -  Unwillingness of adequate contraception during study treatment and at least 2 months
             after treatment

          -  Unwillingness of following procedures of study protocol or follow-up assessments;
             Unable to follow up for long term for psychological, social, family problem or
             geographical reasons

          -  History of treatment with other investigational drugs or investigational medical
             devices prior to 28 days of the first dose of study treatment

          -  In the opinion of the investigator, the patient is an unsuitable candidate to the
             study

          -  ECG finding of QTcF &gt; 450 msec at rest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yohan Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hanmi Pharmaceutical Company Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keunchil Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HM61713</keyword>
  <keyword>Epidermal Growth Factor Receptor mutation positive NSCLC</keyword>
  <keyword>olmutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

